Mylan is not the only drug company reaping financial benefits from excessive price hikes, reports USA Today.
In the past 12 months, 11 drug companies reported profit margins exceeding 25 percent, meaning they kept 25 cents of every dollar brought in after operating costs. Mylan, the Amsterdam-based maker of EpiPens, posted a 20 percent profit margin.
USA Today analyzed drugmakers' profit margins using data from S&P GlobalMarket Intelligence.
Here are the 11 drugmakers with the highest operating profit margins.
- Gilead Sciences (Foster City, Calif.) — 62.7 percent
- Biogen (Cambridge, Mass.) — 49.3 percent
- Amgen (Thousand Oaks, Calif.) — 41.5 percent
- Abbvie (North Chicago, Ill.) —38.9 percent
- Celgene (Summit, N.J.) — 32.3 percent
- Zoetis (Florham Park, N.J.) — 28.1 percent*
- Pfizer (New York City) — 27.8 percent
- Bristol-Myers Squibb (New York City) — 27.3 percent
- Johnson & Johnson (New Brunswick, N.J.) — 27.2 percent
- Regeneron (Tarrytown, N.Y.) — 26.8 percent
- Alexion (Cheshire, Conn.) — 25.3 percent
*Zoetis is a global animal health company.
More articles on supply chain:
EpiPens no longer free for South Carolina's largest school district
Supply chain tip of the week: How to engage physicians in the decision-making process
Mylan vows to reduce patient costs in light of EpiPen pricing scandal